DexCom, Inc. (DXCM) Market Cap & Valuation Ratios
DexCom, Inc. (DXCM) has a market cap of $29.4B, a trailing P/E of 30.9 and a price-to-sales ratio of 5.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DXCMDexCom, Inc.Follow DXCM — free
—
Price chart with a free account
- Market cap
- 29.4B
- P/E TTM
- 30.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Feb, in 109 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| DXCM | 29 | 30.9 | 5.9 | 21.1 | 4.8% | +16% | 23% | 33% |
| BSX | 66 | 18.5 | 3.7 | 14.1 | 5.5% | +14% | 20% | 11% |
| EW | 51 | 51.2 | 7.3 | 29.5 | 2.8% | +15% | 22% | 12% |
| GEHC | 32 | 16.4 | 1.9 | 12.1 | 4.9% | +7% | 13% | 12% |
| STE | 23 | 28.4 | 4.0 | 14.7 | 4.1% | +8% | 19% | 10% |
| ZBH | 19 | 23.9 | 3.0 | 11.2 | 6.4% | +9% | 14% | 5% |
| PEN | 13 | 79.7 | 8.1 | 59.3 | 1.7% | +18% | 12% | 13% |
| GMED | 11 | 20.9 | 3.3 | 11.2 | 6.9% | +20% | 20% | 12% |
| GKOS | 11 | — | 17.0 | — | -0.1% | +42% | -32% | -31% |
| PODD | 10 | 27.9 | 3.5 | 17.5 | 2.7% | +29% | 17% | 22% |
| BIO | 9.9 | — | 3.7 | 42.7 | 3.6% | +1% | 2% | 0.4% |
| Median of these 10 | 25.9 | 3.7 | 14.7 | 3.8% | +14% | 16% | 12% |
P/E 30.9 vs. a peer median of 25.9; EV/Sales 5.9 vs. 3.7. DXCM's own P/E sits at the 5th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesGKOS and BIO have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
DexCom, Inc. — questions
- What is DexCom, Inc.'s market cap?
- $29.4B.
- What is DexCom, Inc.'s P/E ratio?
- 30.9 on trailing twelve-month earnings to 2026-06-30.
- What is DexCom, Inc.'s price-to-sales ratio?
- 5.9.
Every figure on this page comes from DexCom, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.